We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The independent advisory group identified which patient groups are at highest risk of serious illness from COVID-19 and would benefit from new COVID-19 treatments.
Information for patients, healthcare professionals and developers of new medicines
Tax and reporting rules for employers providing medical or dental treatment and insurance
Overview of UK research infrastructure for genomics technologies, and advantages of investment in the UK's life science sector to support new products.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Analysis of people who are potentially suitable for antibody and antiviral out-of-hospital treatments for coronavirus (COVID-19). Includes analysis of their behaviours, opinions and well-being in relation to the COVID-19 pandemic. Data covering attitudes towards treatments and experiences of those who...
Legislation title: Guidance on the application of Plant Protection Products (PPPs) for phytosanitary treatment of oak processionary moth (OPM).
Information on accessing healthcare for visitors to the UK from EU countries, Norway, Iceland, Liechtenstein and Switzerland.
Information for those who have been prescribed Molnupiravir.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).